A phase I trial, open-label and multicenter, evaluating the role of Nivolumab in combination with Pomalidomide and dexamethasone and of Nivolumab in combination with Pomalidomide, dexamethasone and Elotuzumab, in the treatment of patients with refractory or racaid multiple myeloma.
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: PETHEMA FOUNDATION
- Phase: I
- Execution start: 12/01/2017
- End of execution: 30/05/2022
- IP: